M.D. 1996 – 2005 Hebrew University - Hadassah Medical School, Jerusalem

Ph.D. 2004-2009

Hebrew University - Hadassah Medical School, Jerusalem Advisor: Prof. Joseph Shlomai. Articles 1-3

Medical Epidemiology

One year study of courses. No theses was submitted. 2010- 2011 The Hebrew university-Hadassah Braun school of public health and community medicine.

2006-2007 Medical intern Hadassah Hebrew University Hospital , Jerusalem, Israel

2011-2017 Clinical Instructor, Hebrew University Hadassah Medical School

2017- Lecture, Hebrew University Hadassah Medical School

2007-2012

Medical oncology residency Sharett Institute of Oncology, Hadassah Hebrew University Hospital , Jerusalem, Israel

2012- Present Senior medical oncologist Sharett Institute of Oncology, Hadassah Hebrew University Hospital , Jerusalem, Israel

SCIENTIFIC BIOGRAPHY

1. PAST GOALS

I am interested in translating DNA characterization to oncological care. This includes identifying germline mutations in our patient population1; describing the clinical aspects characterizing somatic DNA mutations2 and DNA amplicon structure3 and describing novel genes in repair pathways4. Through collaboration with Dr Amir Eden, Prof. Shema ,Prof. Dor and Prof. Friedman new tumor markers based on cfDNA are developed5,6,7,8. In these collaborations, my role is defining the clinical need and research questions, build the clinical databases and coordinate sample collection.

2. PRESENT ACHIEVEMENTS

DNA characterization as part of oncological clinical care and research today is one of the leading aspects of the Hebrew University-Hadassah Medical Center. I am part of the team leading this effort, clinically by heading the molecular tumor board. By educating on the subject of molecular oncology by initiating the "cancer Hub" and teaching this subject to medical students in several courses. The research capabilities of my laboratory span different methods of massive parallel sequencing including panel sequencing, whole exome sequencing and whole genome sequencing is routinely applied on clinical samples including plasma and formalin fixed paraffin embedded tissue. In parallel, we developed the bioinformatic capabilities of extracting the pertinent data to the research question. The collaboration with different research groups, by applying these methods and those developed by other groups to clinical samples with comprehensive clinical data has established a working group with unique atmosphere and capabilities.

3. FUTURE GOALS

The future research goals include, deepening the understanding of the molecular and genetic mechanisms of DNA amplification in specific patient groups such as MDM2 amplification in liposarcoma as well as in biological models such as Drosophila follicle cells. Characterization of the homologues recombination pathway by examining the germline and somatic mutation profile of specific patients’ groups such as ovarian cancer patients with no identified mutations in known cancer predisposition genes and developing rapid and affordable functional assay for homologues recombination deficiency. Developing a tumor markers and better define tumors based on tissue or cfDNA molecular profile. Participating in a working group that aims to create a comprehensive database of oncological patients with a clinical, molecular and genetic profile as well as a tissue and plasma bank.

The goal of the research in addition to expanding the biological and clinical knowledge is to incorporate technology developed in the Hebrew University to the clinical care of oncological patients.

1. Zick A, Kadouri L, Cohen S, et al. Recurrent TP53 missense mutation in cancer patients of Arab descent. Fam Cancer 2017; 16(2): 295-301.

2. Zick A, Peretz T, Lotem M, et al. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (Baltimore) 2017; 96(20): e6931.

3. Maoz M, Devir M, Inbar M, et al. Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes. Sci Rep 2019; 9(1): 18795.

4. Sherill-Rofe D, Rahat D, Findlay S, et al. Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes. Genome Res 2019; 29(3): 439-48.

5. Lehmann-Werman R, Neiman D, Zemmour H, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proceedings of the National Academy of Sciences of the United States of America 2016; 113(13): E1826-34.

6. Moss J, Magenheim J, Neiman D, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun 2018; 9(1): 5068.

7. Katsman, Orlanski, Martignano, et al. Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing. Genome Biol. 2022 Jul 15;23(1):15.

8. Fedyuk, Nir, Furth, et al. Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics. Nat Biotechnol. 2022 Sep 8. doi: 10.1038/s41587-022-01447-3.

2010 Young researcher award of the Hadassah medical center

2011 Health Education fund in honor of Lou Sand

2013 David S. Lando Memorial Fund

2022 Excellence scholarship in honor of Dr Ofra kalisky

2024 Bequest from Estate of Patricia Fleischman for Gene Therapy Research

English